Parenteral Nutrition Market Worth USD 7.3 Billion by 2024 - Growing Malnutrition Coupled with the Prevalence of Chronic Conditions - Research and Markets

Jul 04, 2016, 10:10 ET from Research and Markets

DUBLIN, July 4, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Parenteral Nutrition Market Analysis, By Nutrition Type (Carbohydrates, Parenteral Lipid Emulsion, Single Dose Amino Acid Solution, Trace Elements, Vitamins and Minerals) And Segment Forecasts To 2024" report to their offering. 
     (Logo: )

The global parenteral nutrition market is expected to reach USD 7.3 billion by 2024, according to this report. The increasing natality rate, the growing malnutrition coupled with the prevalence of chronic conditions such as cancer and gastro-intestinal tract diseases are expected to boost the market over the forecast period. 

The presence of malnourished children in the developing countries leading to the rise in the natality rate and the rising geriatric population suffering from a deficiency of essential nutrients are some of the major factors that are expected to fuel the global parenteral nutrition market. 

According to the WHO around 40.0% patients across the world were malnourished in 2010. The study also indicated that about one-third of the patients in Europe were malnourished in 2012, thereby fuelling industry growth. 

According to the statistics provided by the World Bank Group, India had the highest natality rate followed by China in 2012. Moreover, a consistent increase in the rate of natality was observed in the European countries such as the U.K. and France. Therefore, Asia Pacific and Europe are expected to witness the fastest growth over the forecast. 

North America is expected to witness lucrative growth due to the increase in consumer awareness paired with the increasing healthcare costs. As parenteral nutrition products are available in the home health care sector, it further facilitates the market growth due to the increasing trend in home health care. The increasing incidence of heart diseases is another vital driver. According to the WHO around 49.0% of the American population is endangered with the risk of cardiac arrest. 

Companies Profiled:  

  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • Fresenius Kabi AG
  • Hospira, Inc.
  • Actavis, Inc.
  • Grifols International S.A.
  • Otsuka Pharmaceutical Factory, Inc.
  • Sichuan Kelun Pharmaceutical Co. Ltd.

Key Topics Covered: 

1. Methodology and Scope 

2. Executive Summary 

3. Parenteral Nutrition Industry Outlook 

4. Parenteral nutrition Type Of Nutrition Outlook 

5. Parenteral Nutrition Regional Outlook 

6. Competitive Landscape 

For more information visit

Media Contact: 
Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets